Latanoprost Ophthalmic Solution 0.005%

1 Indications and usage iyuzeh: ™ (latanoprost ophthalmic solution) 0.005% is indicated for the reduction of elevated intraocular pressure (IOP) in patients with open-angle glaucoma or ocular hypertension. IYUZEH is a prostaglandin F2α analogue indicated for the reduction of elevated intraocular pressure in patients with open-angle glaucoma or ocular hypertension. ( 1 )

12.1 Mechanism of Action Latanoprost is a prostaglandin F 2α analogue that is believed to reduce the IOP by increasing the outflow of aqueous humor. Studies in animals and man suggest that the main mechanism of action is increased uveoscleral outflow. Elevated IOP represents a major risk factor for glaucomatous field loss. The higher the level of IOP, the greater the likelihood of optic nerve damage and visual field loss.

Clinical clearance of Latanoprost Ophthalmic Solution 0.005% (Prostaglandin Analog) relies on dual hepatorenal clearance pathway combining glucuronidation and urinary filtration of latanoprost ophthalmic solution 0.005% with a Mean elimination half-life of 10 to 16 hours across adult Latanoprost Ophthalmic Solution 0.005% dosing half-life; patients absorbing at Oral fraction absorbed ranges from 67% to 79% (Latanoprost Ophthalmic Solution 0.005% 50) bioavailability typically observe target onset around oral tmax achieved within 2 to 4 hours following latanoprost ophthalmic solution 0.005% ingestion.

FDA clinical labeling for Latanoprost Ophthalmic Solution 0.005% restricts administration in known hypersensitivity to latanoprost or any other ingredients in this product.; known hypersensitivity to latanoprost or any other ingredients in this product. across 50 ug/mL Solution/ Drops, Prescriber-supervised Latanoprost Ophthalmic Solution 0.005% escalation or taper window, with self-reported patient tracking dominated by nausea (7.9% of reports), headache (6.8% of reports), application-site irritation (6.2% of reports).